Impact of tumor size on effective tumor inhibition with anti-PD-L1 suggests that, in HNSCC, therapeutic regimens combining EBRT with anti-PD-L1 might be more effective when initiated at lower tumor volumes. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.